Mice Model Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

Market Overview

The global mice model market is expected to register a CAGR of 6.8% over the forecast period, 2021-2026.

Due to the current pandemic situation and the urge to develop treatment and vaccines, mice models have been extensively used in the pre-clinical development by various research laboratories and biopharmaceutical industries. According to an article published by the Science Advisory Board in July 2020, researchers were using a strain of SARS-CoV-2 that can infect mice and further using it to produce a new mouse model of infection to help facilitate testing COVID-19 vaccine candidates and therapies.

There is a significant decline in the application of the mice model in drug development apart from COVID-19, as many countries had been in lockdown and suspended trades, implemented travel restrictions, etc., leading to a decline in market capitalizations of major companies across the world, along with a decline in industrial production and pre-clinical trial, which will negatively impact the market growth.

Factors such as increasing innovations in mice models, rising demand for personalized medicine, and growing pipeline of pharmaceutical and biopharmaceutical companies are driving the growth of the mice model market.

Mice models are one of the best small animal models for various infectious diseases, including hepatitis B virus (HBV), hepatitis C virus (HCV), Zika virus, and cytomegalovirus (CMV), among others. Therefore, these mice models are widely used for several different viral investigations in pre-clinical researches.

For instance, in March 2019, the National Institute of Allergy and Infectious Diseases (NIAID) reported funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The growing demand to evaluate the effects of drugs on humans, coupled with a rising focus on studying human-specific infections, therapies, and immune responses, promotes the development and use of humanized mice models.

In addition, major companies are focusing on expanding their product portfolios through novel launches. In July 2019, Taconic Biosciences launched the first commercially available diet-induced NASH rodent model. This novel model will save researchers months of planning and accelerate the clinical development of NASH treatment for liver failure.

Thus, the mice model market is expanding, with the increase in R&D activities in pharmaceutical industries. However, alternatives to animal testing and regulations for the ethical use of animals are expected to be the restraints for the growth of the market.

Scope of the Report

Mice models are biological representations of human diseases or syndromes. Mice and humans have approximately 95% similarity in their DNA. By studying mice that have symptoms of diseases like Alzheimer’s, diabetes, or cancer, we can learn a lot more about how these diseases might be treated in patients. The mice model market is segmented by type (inbred mice, outbred mice, genetically engineered mice, hybrid mice, surgically modified mice, and spontaneous mutant mice), service (breeding, cryopreservation, model in-licensing, genetic testing, and other services), technology (CRISPR/cas9, embryonic stem cell injection, nuclear transfer, and other technologies), application (oncology, cardiovascular studies, neurology, and other applications), and geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Oncology Segment l is Expected to Hold a Significant Market Share Over the Forecast Period

By application, the oncology segment is expected to hold a significant market share. The major factor propelling the segment's growth is the rising burden of cancer, coupled with the increasing adoption of mice models in various oncology-related drug and vaccine development researches. For instance, in August 2020, researchers in the meeting of the American Chemical Society reported that they were developing a new type of immunotherapy for triple-negative breast cancer. The researchers evaluated this therapy in mice models and concluded that it has dramatically extended the mouse's survival in triple-negative breast cancer.

The Institute of Cancer Research, London, stated that mice could be easily genetically altered to study the genetic causes of cancer and reproduce tumor types that naturally occur in humans. For this, they have been incorporating mice models in their pre-clinical trials for years. In 2017, 2018, and 2019, ICR reported using 26,320, 23,525, and 25,771 mice in pre-clinical oncology testing. These mouse models are expected to revolutionize drug discovery research, such as developing and verifying various cancer therapies, including cancer immunotherapy. Thus, the technological developments and funding by the major players to incorporate mice models in various stages of cancer treatment and diagnostic discoveries will boost the market growth.

To understand key trends, Download Sample Report